Yuhan Corporation: Essential Hypertension trials

The registry lists 10 Essential Hypertension studies with Yuhan Corporation as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 2Phase 3 5Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227BRecruitingNCT06441630Phase 3
• Phase III Study to Evaluate the Efficacy and Safety of AD-209RecruitingNCT06348576Phase 3
• A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227BCompletedNCT06884085Phase 1
• Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022CompletedNCT06448962Phase 3
• A Study to Evaluate the Efficacy and Safety of AD-224CompletedNCT06291207Phase 3
• Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionActive, not recruitingNCT06282549
• A Study to Evaluate the Efficacy and Safety of AD-223CompletedNCT06052748Phase 3
• Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionActive, not recruitingNCT06041529Phase 4
• A Study to Evaluate the Efficacy and Safety of AD-209CompletedNCT05631990Phase 2
• Determining the Optimal Dose of AD-209 in Patients With Essential HypertensionCompletedNCT04218552Phase 2